Dabrafenib Combo Shows Complete Responses in BRAF V600+ Metastatic Melanoma
Targeting apoptosis in BRAF V600-mutated melanoma may be considered for future exploration in the post immunotherapy setting, according to an expert at Moffitt Cancer Center.
Nirogacestat Yields Significant Pain Reduction in Desmoid Tumor Population
Nirogacestat also appears to improve progression-free survival compared with placebo among those with desmoid tumors in the phase 3 DeFi trial.
2 Clarke Drive Cranbury, NJ 08512